The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Rational use of adjuvant anti-PD-1: Multi-omics model of recurrence in stage III melanoma.
 
Tuba Gide
No Relationships to Disclose
 
Nurudeen Adegoke
No Relationships to Disclose
 
Michael Xie
No Relationships to Disclose
 
Yizhe Mao
No Relationships to Disclose
 
Grace Attrill
No Relationships to Disclose
 
Nigel Maher
No Relationships to Disclose
 
Robyn Saw
Honoraria - Australian Clinical Laboratories; Merck Sharp & Dohme
Consulting or Advisory Role - MSD
 
Ismael A. Vergara
Patents, Royalties, Other Intellectual Property - US11035005B2 Cancer diagnostics using biomarkers US10513737B2 Cancer diagnostics using non-coding transcripts US11145412B2 Methods for the diagnosis and prognosis of melanoma from topical skin swabs
 
Matteo Carlino
Honoraria - Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; IDEAYA Biosciences; Innovent Biologics; Medison; Medison; Merck Serono; Moderna Therapeutics; MSD; Nektar; Novartis; OncoSec; Pierre Fabre; QBiotics; Regeneron; Roche; Sanofi
 
Serigne Lo
Consulting or Advisory Role - Skyline Diagnostics
 
Ines Esteves Domingues Pires da Silva
Honoraria - MSD
Consulting or Advisory Role - MSD; Regeneron; Strand Therapeutics
 
Jorja Braden
No Relationships to Disclose
 
Alexander Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; QBiotics; Roche
 
Richard Scolyer
Employment - Sydney Local Health District / Royal Prince Alfred Hospital
Leadership - Melanoma Institute Australia
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb GesmbH (Austria); Bristol-Myers Squibb SA (Switzerland); Evaxion Biotech; GlaxoSmithKline; IO Biotech; Merck Sharp & Dohme; metaoptima; MSD Sharp & Dohme (Australia) Pty Limited; Myriad Genetics; NeraCare GmbH; Novartis; Novartis; Novartis; Novartis; Provectus Biopharmaceuticals; QBiotics; Roche; Skyline Diagnostics
Research Funding - Melanoma Research Alliance (MRA); National Health and Medical Research Council; National Health and Medical Research Council; Tour de Cure
Patents, Royalties, Other Intellectual Property - Pending Application (as at 5.9.24): Application number 2024901602, Title: Methods for identifying skin cancer, administering biopsies and treating skin cancer. (Inst)
 
Georgina Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Evaxion Biotech; GI Innovation Inc; Hexal; Highlight Therapeutics; Immunocore Ireland Limited; Innovent Biologics; IO Biotech; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Regeneron; Scancell LImited; Skyline Diagnostics
 
James Wilmott
No Relationships to Disclose